image missing
HOME SN-BRIEFS SYSTEM
OVERVIEW
EFFECTIVE
MANAGEMENT
PROGRESS
PERFORMANCE
PROBLEMS
POSSIBILITIES
STATE
CAPITALS
FLOW
ACTIVITIES
FLOW
ACTORS
PETER
BURGESS
SiteNav SitNav (0) SitNav (1) SitNav (2) SitNav (3) SitNav (4) SitNav (5) SitNav (6) SitNav (7) SitNav (8)
Date: 2025-05-11 Page is: DBtxt001.php txt00018585

The Covid-19 Emergency
Vaccine Development

British American Tobacco Working on COVID-19 Vaccine Using Tobacco Leaves

Burgess COMMENTARY

Peter Burgess
British American Tobacco Working on COVID-19 Vaccine Using Tobacco Leaves (Reuters) - British American Tobacco, the maker of Dunhill and Lucky Strike cigarettes, said on Wednesday its U.S. biotech unit was working on a potential vaccine for COVID-19 using proteins extracted from tobacco leaves. Kentucky BioProcessing (KBP), the unit developing the vaccine, could produce between 1 million and 3 million doses per week starting in June, the company said, with support from government agencies and the right manufacturers. British American Tobacco said KBP, a division of BAT's U.S. unit Reynolds American Inc, would develop the vaccine on a not-for-profit basis. The vaccine, currently undergoing pre-clinical testing, uses a cloned portion of COVID-19's genetic sequence to create an antigen that is then inserted into tobacco plants for reproduction. ADVERTISEMENT Continue reading the main story Once harvested, the antigens - substances that induce an immune response in the body - are extracted and purified and inserted into the body to fight the virus, the company said, adding that the formulation it is developing is stable at room temperature, unlike conventional vaccines which often require refrigeration. KBP made headlines a few years back when it said https://www.reuters.com/article/health-ebola-tobacco-idINKBN0G608V20140806 it had created an effective treatment against Ebola called ZMapp, in conjunction with California-based Mapp Biopharmaceuticals. The drug is yet to get U.S. Food and Drug Administration approval. 'We believe we have made a significant break-through with our tobacco plant technology platform and stand ready to work with governments and all stakeholders to help win the war against COVID-19,' David O'Reilly, director of Scientific Research at BAT, said in a statement. BAT said it was working with the U.S. Food and Drug Administration on the next steps and was also engaged with U.K. health authorities to bring its vaccine to clinical studies as soon as possible. (Reporting by Siddharth Cavale in Bengaluru; Editing by Bernard Orr) Editors’ Picks ‘I Saw Another Woman on the Platform Do an Obvious Double Take’ She Wanted an Investment Property She Could Live In. Here’s Where She Found It. Celebrity Culture Is Burning Continue reading the main story
By Reuters
April 1, 2020, 5:21 a.m. ET
The text being discussed is available at

and
SITE COUNT<
Amazing and shiny stats
Blog Counters Reset to zero January 20, 2015
TrueValueMetrics (TVM) is an Open Source / Open Knowledge initiative. It has been funded by family and friends. TVM is a 'big idea' that has the potential to be a game changer. The goal is for it to remain an open access initiative.
WE WANT TO MAINTAIN AN OPEN KNOWLEDGE MODEL
A MODEST DONATION WILL HELP MAKE THAT HAPPEN
The information on this website may only be used for socio-enviro-economic performance analysis, education and limited low profit purposes
Copyright © 2005-2021 Peter Burgess. All rights reserved.